Computerized Cognitive Assessment Tools Market 2017 Global Trend, Size, Segmentation and Opportunities Forecast To 2022

This report covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies

PUNE, INDIA, October 24, 2017 /EINPresswire.com/ — This report studies the global Computerized Cognitive Assessment Tools market, analyzes and researches the Computerized Cognitive Assessment Tools development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/2408554-global-computerized-cognitive-assessment-tools-market-size-status-and-forecast-2022

Driveable Assessment Centres Inc.
Cambridge Cognition Holdings plc
CogniFit Ltd.
Brain, Performance and Nutrition Research Centre
Tietronix Software Inc
AnthroTronix Inc.

Market segment by Regions/Countries, this report covers
United States
EU
Japan
China
India
Southeast Asia

Market segment by Application, Computerized Cognitive Assessment Tools can be split into
Clinicians
Academic Researchers
Others

Make an enquiry of this Report @ https://www.wiseguyreports.com/enquiry/2408554-global-computerized-cognitive-assessment-tools-market-size-status-and-forecast-2022

If you have any special requirements, please let us know and we will offer you the report as you want.

Table of Contents

Global Computerized Cognitive Assessment Tools Market Size, Status and Forecast 2022
1 Industry Overview of Computerized Cognitive Assessment Tools
1.1 Computerized Cognitive Assessment Tools Market Overview
1.1.1 Computerized Cognitive Assessment Tools Product Scope
1.1.2 Market Status and Outlook
1.2 Global Computerized Cognitive Assessment Tools Market Size and Analysis by Regions
1.2.1 United States
1.2.2 EU
1.2.3 Japan
1.2.4 China
1.2.5 India
1.2.6 Southeast Asia
1.3 Computerized Cognitive Assessment Tools Market by End Users/Application
1.3.1 Clinicians
1.3.2 Academic Researchers
1.3.3 Others

2 Global Computerized Cognitive Assessment Tools Competition Analysis by Players
2.1 Computerized Cognitive Assessment Tools Market Size (Value) by Players (2016 and 2017)
2.2 Competitive Status and Trend
2.2.1 Market Concentration Rate
2.2.2 Product/Service Differences
2.2.3 New Entrants
2.2.4 The Technology Trends in Future

3 Company (Top Players) Profiles
3.1 Driveable Assessment Centres Inc.
3.1.1 Company Profile
3.1.2 Main Business/Business Overview
3.1.3 Products, Services and Solutions
3.1.4 Computerized Cognitive Assessment Tools Revenue (Value) (2012-2017)
3.1.5 Recent Developments
3.2 Cambridge Cognition Holdings plc
3.2.1 Company Profile
3.2.2 Main Business/Business Overview
3.2.3 Products, Services and Solutions
3.2.4 Computerized Cognitive Assessment Tools Revenue (Value) (2012-2017)
3.2.5 Recent Developments
3.3 CogniFit Ltd.
3.3.1 Company Profile
3.3.2 Main Business/Business Overview
3.3.3 Products, Services and Solutions
3.3.4 Computerized Cognitive Assessment Tools Revenue (Value) (2012-2017)
3.3.5 Recent Developments
3.4 Brain, Performance and Nutrition Research Centre
3.4.1 Company Profile
3.4.2 Main Business/Business Overview
3.4.3 Products, Services and Solutions
3.4.4 Computerized Cognitive Assessment Tools Revenue (Value) (2012-2017)
3.4.5 Recent Developments
3.5 Tietronix Software Inc
3.5.1 Company Profile
3.5.2 Main Business/Business Overview
3.5.3 Products, Services and Solutions
3.5.4 Computerized Cognitive Assessment Tools Revenue (Value) (2012-2017)
3.5.5 Recent Developments
3.6 AnthroTronix Inc.
3.6.1 Company Profile
3.6.2 Main Business/Business Overview
3.6.3 Products, Services and Solutions
3.6.4 Computerized Cognitive Assessment Tools Revenue (Value) (2012-2017)
3.6.5 Recent Developments

4 Global Computerized Cognitive Assessment Tools Market Size by Application (2012-2017)
4.1 Global Computerized Cognitive Assessment Tools Market Size by Application (2012-2017)
4.2 Potential Application of Computerized Cognitive Assessment Tools in Future
4.3 Top Consumer/End Users of Computerized Cognitive Assessment Tools

5 United States Computerized Cognitive Assessment Tools Development Status and Outlook
5.1 United States Computerized Cognitive Assessment Tools Market Size (2012-2017)
5.2 United States Computerized Cognitive Assessment Tools Market Size and Market Share by Players (2016 and 2017)

……Continued

Purchase Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=2408554

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Next Generation Implants (NGI) Global Market 2017 Key Players, Demand, Share, Trend, Segmentation and Forecast to 2022

This report covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies

PUNE, INDIA, October 24, 2017 /EINPresswire.com/ — This report studies the global Next Generation Implants (NGI) market, analyzes and researches the Next Generation Implants (NGI) development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/2407829-global-next-generation-implants-ngi-market-size-status-and-forecast-2022

Abbott Laboratories
Arthrex
Biotronik SE & Co. KG
BOSTON SCIENTIFIC CORPORATION
C. R. BARD, INC.
DANAHER CORPORATION
DENTSPLY SIRNA Inc.
Edwards Lifesciences Corporation
Globus Medical Inc.
Integer Holdings Corporation
Integra LifeSciences Corporation
Institut Straumann AG
LifeNet Health, Inc.
LivaNova PLC
Novartis International AG

Market segment by Regions/Countries, this report covers
United States
EU
Japan
China
India
Southeast Asia

Market segment by Type, the product can be split into
Metals & Metal Alloys
Ceramics
Polymers
Biologics
Others

Market segment by Application, Next Generation Implants (NGI) can be split into
Orthopedic Implants
Cardiovascular Implants
Ocular Implants
Dental Implants

Make an enquiry of this Report @ https://www.wiseguyreports.com/enquiry/2407829-global-next-generation-implants-ngi-market-size-status-and-forecast-2022

If you have any special requirements, please let us know and we will offer you the report as you want.

Table of Contents

Global Next Generation Implants (NGI) Market Size, Status and Forecast 2022
1 Industry Overview of Next Generation Implants (NGI)
1.1 Next Generation Implants (NGI) Market Overview
1.1.1 Next Generation Implants (NGI) Product Scope
1.1.2 Market Status and Outlook
1.2 Global Next Generation Implants (NGI) Market Size and Analysis by Regions
1.2.1 United States
1.2.2 EU
1.2.3 Japan
1.2.4 China
1.2.5 India
1.2.6 Southeast Asia
1.3 Next Generation Implants (NGI) Market by Type
1.3.1 Metals & Metal Alloys
1.3.2 Ceramics
1.3.3 Polymers
1.3.4 Biologics
1.3.5 Others
1.4 Next Generation Implants (NGI) Market by End Users/Application
1.4.1 Orthopedic Implants
1.4.2 Cardiovascular Implants
1.4.3 Ocular Implants
1.4.4 Dental Implants

2 Global Next Generation Implants (NGI) Competition Analysis by Players
2.1 Next Generation Implants (NGI) Market Size (Value) by Players (2016 and 2017)
2.2 Competitive Status and Trend
2.2.1 Market Concentration Rate
2.2.2 Product/Service Differences
2.2.3 New Entrants
2.2.4 The Technology Trends in Future

3 Company (Top Players) Profiles
3.1 Abbott Laboratories
3.1.1 Company Profile
3.1.2 Main Business/Business Overview
3.1.3 Products, Services and Solutions
3.1.4 Next Generation Implants (NGI) Revenue (Value) (2012-2017)
3.1.5 Recent Developments
3.2 Arthrex
3.2.1 Company Profile
3.2.2 Main Business/Business Overview
3.2.3 Products, Services and Solutions
3.2.4 Next Generation Implants (NGI) Revenue (Value) (2012-2017)
3.2.5 Recent Developments
3.3 Biotronik SE & Co. KG
3.3.1 Company Profile
3.3.2 Main Business/Business Overview
3.3.3 Products, Services and Solutions
3.3.4 Next Generation Implants (NGI) Revenue (Value) (2012-2017)
3.3.5 Recent Developments
3.4 BOSTON SCIENTIFIC CORPORATION
3.4.1 Company Profile
3.4.2 Main Business/Business Overview
3.4.3 Products, Services and Solutions
3.4.4 Next Generation Implants (NGI) Revenue (Value) (2012-2017)
3.4.5 Recent Developments
3.5 C. R. BARD, INC.
3.5.1 Company Profile
3.5.2 Main Business/Business Overview
3.5.3 Products, Services and Solutions
3.5.4 Next Generation Implants (NGI) Revenue (Value) (2012-2017)
3.5.5 Recent Developments
3.6 DANAHER CORPORATION
3.6.1 Company Profile
3.6.2 Main Business/Business Overview
3.6.3 Products, Services and Solutions
3.6.4 Next Generation Implants (NGI) Revenue (Value) (2012-2017)
3.6.5 Recent Developments
3.7 DENTSPLY SIRNA Inc.
3.7.1 Company Profile
3.7.2 Main Business/Business Overview
3.7.3 Products, Services and Solutions
3.7.4 Next Generation Implants (NGI) Revenue (Value) (2012-2017)
3.7.5 Recent Developments
3.8 Edwards Lifesciences Corporation
3.8.1 Company Profile
3.8.2 Main Business/Business Overview
3.8.3 Products, Services and Solutions
3.8.4 Next Generation Implants (NGI) Revenue (Value) (2012-2017)
3.8.5 Recent Developments
3.9 Globus Medical Inc.
3.9.1 Company Profile
3.9.2 Main Business/Business Overview
3.9.3 Products, Services and Solutions
3.9.4 Next Generation Implants (NGI) Revenue (Value) (2012-2017)
3.9.5 Recent Developments
3.10 Integer Holdings Corporation
3.10.1 Company Profile
3.10.2 Main Business/Business Overview
3.10.3 Products, Services and Solutions
3.10.4 Next Generation Implants (NGI) Revenue (Value) (2012-2017)
3.10.5 Recent Developments
3.11 Integra LifeSciences Corporation
3.12 Institut Straumann AG
3.13 LifeNet Health, Inc.
3.14 LivaNova PLC
3.15 Novartis International AG

4 Global Next Generation Implants (NGI) Market Size by Type and Application (2012-2017)
4.1 Global Next Generation Implants (NGI) Market Size by Type (2012-2017)
4.2 Global Next Generation Implants (NGI) Market Size by Application (2012-2017)
4.3 Potential Application of Next Generation Implants (NGI) in Future
4.4 Top Consumer/End Users of Next Generation Implants (NGI)

5 United States Next Generation Implants (NGI) Development Status and Outlook
5.1 United States Next Generation Implants (NGI) Market Size (2012-2017)
5.2 United States Next Generation Implants (NGI) Market Size and Market Share by Players (2016 and 2017)

……Continued

Purchase Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=2407829

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Collagen Protein Peptides Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2022

Wiseguyreports.Com Adds “Collagen Protein Peptides Market: Demand, Growth, Opportunities and Analysis of Top Key Player Forecast To 2022”

PUNE, INDIA, October 24, 2017 /EINPresswire.com/ — Global Collagen Protein Peptides Industry

Latest Report on Collagen Protein Peptides Market Global Analysis & 2022 Forecast Research Study

This report studies Collagen Protein Peptides in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.

This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering
Rousselot
Cargill Incorporated
Weishardt Group
Tessenderlo Group
GELITA
Lapi Gelatine
Gelnex
Kewpie Corporation
ITALGELATINE
Danish Crown

Try Sample Report @  https://www.wiseguyreports.com/sample-request/2416903-global-collagen-protein-peptides-market-professional-survey-report-2017

By types, the market can be split into
Cattle Hide & Bone
Pigskin
Poultry & Fish
Others

By Application, the market can be split into
Snacks & Cereals
Dairy Products
Beverages
Meat & Poultry Products

By Regions, this report covers (we can add the regions/countries as you want)
North America
China
Europe
Southeast Asia
Japan
India

Some points from table of content:

Global Collagen Protein Peptides Market Professional Survey Report 2017
1 Industry Overview of Collagen Protein Peptides
1.1 Definition and Specifications of Collagen Protein Peptides
1.1.1 Definition of Collagen Protein Peptides
1.1.2 Specifications of Collagen Protein Peptides
1.2 Classification of Collagen Protein Peptides
1.2.1 Cattle Hide & Bone
1.2.2 Pigskin
1.2.3 Poultry & Fish
1.2.4 Others
1.3 Applications of Collagen Protein Peptides
1.3.1 Snacks & Cereals
1.3.2 Dairy Products
1.3.3 Beverages
1.3.4 Meat & Poultry Products
1.4 Market Segment by Regions
1.4.1 North America
1.4.2 China
1.4.3 Europe
1.4.4 Southeast Asia
1.4.5 Japan
1.4.6 India

For Detailed Reading Please visit WiseGuy Reports @     https://www.wiseguyreports.com/reports/2416903-global-collagen-protein-peptides-market-professional-survey-report-2017

2 Manufacturing Cost Structure Analysis of Collagen Protein Peptides
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Collagen Protein Peptides
2.3 Manufacturing Process Analysis of Collagen Protein Peptides
2.4 Industry Chain Structure of Collagen Protein Peptides

3 Technical Data and Manufacturing Plants Analysis of Collagen Protein Peptides
3.1 Capacity and Commercial Production Date of Global Collagen Protein Peptides Major Manufacturers in 2016
3.2 Manufacturing Plants Distribution of Global Collagen Protein Peptides Major Manufacturers in 2016
3.3 R&D Status and Technology Source of Global Collagen Protein Peptides Major Manufacturers in 2016
3.4 Raw Materials Sources Analysis of Global Collagen Protein Peptides Major Manufacturers in 2016

4 Global Collagen Protein Peptides Overall Market Overview
4.1 2012-2017E Overall Market Analysis
4.2 Capacity Analysis
4.2.1 2012-2017E Global Collagen Protein Peptides Capacity and Growth Rate Analysis
4.2.2 2016 Collagen Protein Peptides Capacity Analysis (Company Segment)
4.3 Sales Analysis
4.3.1 2012-2017E Global Collagen Protein Peptides Sales and Growth Rate Analysis
4.3.2 2016 Collagen Protein Peptides Sales Analysis (Company Segment)
4.4 Sales Price Analysis
4.4.1 2012-2017E Global Collagen Protein Peptides Sales Price
4.4.2 2016 Collagen Protein Peptides Sales Price Analysis (Company Segment)

5 Collagen Protein Peptides Regional Market Analysis
5.1 North America Collagen Protein Peptides Market Analysis
5.1.1 North America Collagen Protein Peptides Market Overview
5.1.2 North America 2012-2017E Collagen Protein Peptides Local Supply, Import, Export, Local Consumption Analysis
5.1.3 North America 2012-2017E Collagen Protein Peptides Sales Price Analysis
5.1.4 North America 2016 Collagen Protein Peptides Market Share Analysis
5.2 China Collagen Protein Peptides Market Analysis
5.2.1 China Collagen Protein Peptides Market Overview
5.2.2 China 2012-2017E Collagen Protein Peptides Local Supply, Import, Export, Local Consumption Analysis
5.2.3 China 2012-2017E Collagen Protein Peptides Sales Price Analysis
5.2.4 China 2016 Collagen Protein Peptides Market Share Analysis
5.3 Europe Collagen Protein Peptides Market Analysis
5.3.1 Europe Collagen Protein Peptides Market Overview
5.3.2 Europe 2012-2017E Collagen Protein Peptides Local Supply, Import, Export, Local Consumption Analysis
5.3.3 Europe 2012-2017E Collagen Protein Peptides Sales Price Analysis
5.3.4 Europe 2016 Collagen Protein Peptides Market Share Analysis
5.4 Southeast Asia Collagen Protein Peptides Market Analysis
5.4.1 Southeast Asia Collagen Protein Peptides Market Overview
5.4.2 Southeast Asia 2012-2017E Collagen Protein Peptides Local Supply, Import, Export, Local Consumption Analysis

Continued…….

For more information or any query mail at sales@wiseguyreports.com

About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:
Norah Trent
+1 646 845 9349 / +44 208 133 9349
Follow on LinkedIn: https://www.linkedin.com/company/wise-guy-research-consultants-pvt-ltd-?trk=biz-companies-cym

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Global Drug Discovery Informatics 2017 Industry Trends, Sales, Supply, Demand, Analysis & Forecast to 2022

WiseGuyReports.com adds “Drug Discovery Informatics Market 2017 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2022”

PUNE, INDIA, October 24, 2017 /EINPresswire.com/ — Summary

WiseGuyReports.com adds “Drug Discovery Informatics Market 2017 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2022” reports to its database.

This report studies the global Drug Discovery Informatics market, analyzes and researches the Drug Discovery Informatics development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like
ChemAxon
GVK Biosciences
Jubilant Biosys
Selvita
Certara
Infosys
Albany Molecular Research
Boehringer Ingelheim
DiscoverX
Charles River Laboratories
Covance
Collaborative Drug Discovery
Novo Informatics
UCB
Evotec

Request a Sample Report @   https://www.wiseguyreports.com/sample-request/2408560-global-drug-discovery-informatics-market-size-status-and-forecast-2022

Market segment by Regions/Countries, this report covers
United States
EU
Japan
China
India
Southeast Asia

Market segment by Type, Drug Discovery Informatics can be split into
Outsourced Informatics
In-House Informatics

Market segment by Application, Drug Discovery Informatics can be split into
University
Research Center
Hospital
Pharmaceutical Companies
Others

At Any Query @ https://www.wiseguyreports.com/enquiry/2408560-global-drug-discovery-informatics-market-size-status-and-forecast-2022

Table of Contents 

Global Drug Discovery Informatics Market Size, Status and Forecast 2022
1 Industry Overview of Drug Discovery Informatics
1.1 Drug Discovery Informatics Market Overview
1.1.1 Drug Discovery Informatics Product Scope
1.1.2 Market Status and Outlook
1.2 Global Drug Discovery Informatics Market Size and Analysis by Regions
1.2.1 United States
1.2.2 EU
1.2.3 Japan
1.2.4 China
1.2.5 India
1.2.6 Southeast Asia
1.3 Drug Discovery Informatics Market by Type
1.3.1 Outsourced Informatics
1.3.2 In-House Informatics
1.4 Drug Discovery Informatics Market by End Users/Application
1.4.1 University
1.4.2 Research Center
1.4.3 Hospital
1.4.4 Pharmaceutical Companies
1.4.5 Others

2 Global Drug Discovery Informatics Competition Analysis by Players
2.1 Drug Discovery Informatics Market Size (Value) by Players (2016 and 2017)
2.2 Competitive Status and Trend
2.2.1 Market Concentration Rate
2.2.2 Product/Service Differences
2.2.3 New Entrants
2.2.4 The Technology Trends in Future

3 Company (Top Players) Profiles
3.1 ChemAxon
3.1.1 Company Profile
3.1.2 Main Business/Business Overview
3.1.3 Products, Services and Solutions
3.1.4 Drug Discovery Informatics Revenue (Value) (2012-2017)
3.1.5 Recent Developments
3.2 GVK Biosciences
3.2.1 Company Profile
3.2.2 Main Business/Business Overview
3.2.3 Products, Services and Solutions
3.2.4 Drug Discovery Informatics Revenue (Value) (2012-2017)
3.2.5 Recent Developments
3.3 Jubilant Biosys
3.3.1 Company Profile
3.3.2 Main Business/Business Overview
3.3.3 Products, Services and Solutions
3.3.4 Drug Discovery Informatics Revenue (Value) (2012-2017)
3.3.5 Recent Developments
3.4 Selvita
3.4.1 Company Profile
3.4.2 Main Business/Business Overview
3.4.3 Products, Services and Solutions
3.4.4 Drug Discovery Informatics Revenue (Value) (2012-2017)
3.4.5 Recent Developments
3.5 Certara
3.5.1 Company Profile
3.5.2 Main Business/Business Overview
3.5.3 Products, Services and Solutions
3.5.4 Drug Discovery Informatics Revenue (Value) (2012-2017)
3.5.5 Recent Developments
3.6 Infosys
3.6.1 Company Profile
3.6.2 Main Business/Business Overview
3.6.3 Products, Services and Solutions
3.6.4 Drug Discovery Informatics Revenue (Value) (2012-2017)
3.6.5 Recent Developments
3.7 Albany Molecular Research
3.7.1 Company Profile
3.7.2 Main Business/Business Overview
3.7.3 Products, Services and Solutions
3.7.4 Drug Discovery Informatics Revenue (Value) (2012-2017)
3.7.5 Recent Developments
3.8 Boehringer Ingelheim
3.8.1 Company Profile
3.8.2 Main Business/Business Overview
3.8.3 Products, Services and Solutions
3.8.4 Drug Discovery Informatics Revenue (Value) (2012-2017)
3.8.5 Recent Developments
3.9 DiscoverX
3.9.1 Company Profile
3.9.2 Main Business/Business Overview
3.9.3 Products, Services and Solutions
3.9.4 Drug Discovery Informatics Revenue (Value) (2012-2017)
3.9.5 Recent Developments
3.10 Charles River Laboratories
3.10.1 Company Profile
3.10.2 Main Business/Business Overview
3.10.3 Products, Services and Solutions
3.10.4 Drug Discovery Informatics Revenue (Value) (2012-2017)
3.10.5 Recent Developments
3.11 Covance
3.12 Collaborative Drug Discovery
3.13 Novo Informatics
3.14 UCB
3.15 Evotec

4 Global Drug Discovery Informatics Market Size by Type and Application (2012-2017)
4.1 Global Drug Discovery Informatics Market Size by Type (2012-2017)
4.2 Global Drug Discovery Informatics Market Size by Application (2012-2017)
4.3 Potential Application of Drug Discovery Informatics in Future
4.4 Top Consumer/End Users of Drug Discovery Informatics

Continued….

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=2408560

Contact Us: sales@wiseguyreports.com

Ph: +1-646-845-9349 (US) ; Ph: +44 208 133 9349 (UK)

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Clostridium difficile Infections Market 2017 Strategies 2017 by Analyzing the Performance of Various Competitors 2026

Clostridium difficile Infections

PUNE, MAHARASHTRA, INDIA, October 24, 2017 /EINPresswire.com/ —

SUMMARY

WiseGuyReports published new report, titled “OpportunityAnalyzer: Clostridium difficile Infections”

Clostridium difficile, a Gram-positive, spore-forming, toxin-producing, non-invasive, anaerobic bacterium, is the causative organism of C. difficile infection (CDI), which is commonly associated with colitis, as well as C. difficile-associated diarrhea (CDAD. CDIs begin with colonization of the intestinal tract with C. difficile through community-acquired or healthcare-associated means. Observed most frequently in healthcare settings, CDIs often occur when normal intestinal flora are disrupted by antibiotic administration, which can give C. difficile a competitive growth advantage if patients are exposed to the pathogen. Since 2000, CDIs have become more frequent, more severe, more difficult to treat using existing therapies, and more likely to recur than previously described. These realities, along with increasing threat of antibiotic resistance, underscore the importance of developing CDI-specific therapies and bringing them to market.
During the 10-year forecast period, there are nine products that are on track to launch, contributing to significant growth within the market. The launch of the first prophylactic options for the prevention of CDIs, beginning with Sanofi Pasteur’s vaccine ACAM-CDIFF in 2019, will fulfill a major unmet need, and will have a significant effect on the overall size of the CDI market. The expected launch of the first microbiologic therapies, leveraging the efficacy associated with FMT with respect to CDI recurrence rates, will also have an effect on the overall treatment landscape during the forecast period. In 2026, antibiotics are expected to have remained the highest grossing product class in the CDI market, with novel vaccines also contributing a significant market share.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2401033-opportunityanalyzer-clostridium-difficile-infections-opportunity-analysis-and-forecasts-to-2026

Scope

– Overview of CDI, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
– Topline CDI market revenue from 2016-2026. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
– Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting CDI therapeutics and prophylactics sales in the 7MM.
– Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
– Analysis of the current and future market competition in the global CDI therapeutics and prophylactics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key points to buy

The report will enable you to –

– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving the global CDI therapeutics and prophylactics market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the CDI therapeutics and prophylactics market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Table of Contents
2 Executive Summary
3 Introduction
4 Disease Overview
5 Epidemiology
6 Current Treatment Options
7 Unmet Needs Assessment and Opportunity Analysis
8 Research and Development Strategies
9 Pipeline Assessment
10 Pipeline Valuation Analysis
11 Appendix

..CONTINUED

About Us

Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Global Ambulatory Surgery Center 2017 Industry Trends, Sales, Supply, Demand, Analysis & Forecast to 2022

WiseGuyReports.com adds “Ambulatory Surgery Center Market 2017 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2022”

PUNE, INDIA, October 24, 2017 /EINPresswire.com/ —

Summary

WiseGuyReports.com adds “Ambulatory Surgery Center Market 2017 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2022” reports to its database.

The global ambulatory surgical centers (ASCs) market is currently witnessing relatively fast growth mainly due to an increasing demand for quick, cost-effective, and high-quality medical services as a viable alternative to inpatient care. In terms of revenue the global ambulatory surgical centers market is projected to expand at a CAGR of 3.95% during the forecast period (2012–2022) and is expected to be valued at 94.5 B USD by the end of 2022– projecting a 1.47X increase during this period. Market growth is likely to be driven largely by the rise in healthcare spending along with a growing number of ASCs.

This report studies Ambulatory Surgery Center in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with revenue and market share for each manufacturer, covering
AmSurg
THC
HCA Healthcare
Mednax
Team Health
Surgical Care Affiliates
QHC
Surgery Partners
Medical Facilities
Terveystalo Healthcare
SurgCenter Development
Healthway Medical
Eifelhoehen-Klinik

Request a Sample Report @   https://www.wiseguyreports.com/sample-request/1104328-global-ambulatory-surgery-center-market-size-status-and-forecast-2022

Market Segment by Regions, this report splits Global into several key Regions, with market size, market share and growth rate of Ambulatory Surgery Center in these regions, from 2012 to 2022 (forecast), like
North America
China
Europe
Japan
Southeast Asia
India

Split by Product Types, with market size, market share and growth rate of each type, can be divided into
Single-specialty Centers
Multi-specialty Centers

Split by applications, this report focuses on consumption, market share and growth rate of Ambulatory Surgery Center in each application, can be divided into
Ophthalmology
Pain Management
Gastroenterology
Orthopedics
Others

At Any Query @ https://www.wiseguyreports.com/enquiry/1104328-global-ambulatory-surgery-center-market-size-status-and-forecast-2022

Table of Contents 

1 Industry Overview 1
    1.1 Ambulatory Surgery Center Market Overview 1
1.1.1 Ambulatory Surgery Center Scope 1
1.1.2 Market Status and Outlook 1
1.2 Global Ambulatory Surgery Center Market Size and Analysis by Regions (2012-2017) 3
1.2.1 North America Ambulatory Surgery Center Market Status and Outlook 5
1.2.2 Europe Ambulatory Surgery Center Market Status and Outlook 6
1.2.3 Japan Ambulatory Surgery Center Market Status and Outlook 7
1.2.4 China Ambulatory Surgery Center Market Status and Outlook 8
1.2.5 Southeast Asia Ambulatory Surgery Center Market Status and Outlook 9
1.2.6 India Ambulatory Surgery Center Market Status and Outlook 10
1.3 Classification of Ambulatory Surgery Center by Product 10
1.3.1 Global Ambulatory Surgery Center Revenue (M USD) and Growth Comparison by Type (2012-2022) 10
1.3.2 Global Ambulatory Surgery Center Market Share by Type 11
1.3.3 Single-specialty Centers 12
1.3.4 Multi-specialty Centers 12
1.4 Ambulatory Surgery Center Market by End Users/Application 13
1.4.1 Ophthalmology 15
1.4.2 Pain Management 16
1.4.3 Gastroenterology 17
1.4.4 Orthopedics 18
2 Global Ambulatory Surgery Center Competition Analysis by Players 20
    2.1 Global Ambulatory Surgery Center Market Size (M USD) by Players (2012-2017) 20
2.2 Global Ambulatory Surgery Center Gross Margin by Players (2012-2017) 22
2.3 Competitive Status and Trend 25
2.3.1 Market Concentration Rate 25
2.3.2 Mergers & Acquisitions, Expansion 27
2.3.3 The Development Trends in Future 29
3 Analysis of Ambulatory Surgery Center Industry Key Manufacturers 30
3.1 AmSurg 30
      3.1.1 Company Profile 30
3.1.2 Ambulatory Surgery Center Information 31
3.1.3 Revenue, Cost, Gross and Gross Margin 32
    3.2 THC 33
      3.2.1 Company Profile 33
3.2.2 Ambulatory Surgery Center Information 34
3.2.3 Revenue, Cost, Gross and Gross Margin 35
    3.3 HCA Healthcare 36
      3.3.1 Company Profile 36
3.3.2 Ambulatory Surgery Center Information 39
3.3.3 Revenue, Cost, Gross and Gross Margin 39
    3.4 Mednax 41
      3.4.1 Company Profile 41
3.4.2 Ambulatory Surgery Center Information 42
3.4.3 Revenue, Cost, Gross and Gross Margin 42
    3.5 Team Health 44
      3.5.1 Company Profile 44
3.5.2 Ambulatory Surgery Center Information 45
3.5.3 Revenue, Cost, Gross and Gross Margin 45
    3.6 Surgical Care Affiliates 47
      3.6.1 Company Profile 47
3.6.2 Ambulatory Surgery Center Information 48
3.6.3 Revenue, Cost, Gross and Gross Margin 49
    3.7 QHC 50
      3.7.1 Company Profile 50
3.7.2 Ambulatory Surgery Center Information 51
3.7.3 Revenue, Cost, Gross and Gross Margin 52
    3.8 Surgery Partners 53
      3.8.1 Company Profile 53
3.8.2 Ambulatory Surgery Center Information 54
3.8.3 Revenue, Cost, Gross and Gross Margin 55
    3.9 Medical Facilities 56
      3.9.1 Company Profile 56
3.9.2 Ambulatory Surgery Center Information 58
3.9.3 Revenue, Cost, Gross and Gross Margin 58
    3.10 Terveystalo Healthcare 60
      3.10.1 Company Profile 60
3.10.2 Ambulatory Surgery Center Information 61
3.10.3 Revenue, Cost, Gross and Gross Margin 61
    3.11 SurgCenter Development 63
      3.11.1 Company Profile 63
3.11.2 Ambulatory Surgery Center Information 64
3.11.3 Revenue, Cost, Gross and Gross Margin 64
    3.12 Healthway Medical 66
      3.12.1 Company Profile 66
3.12.2 Ambulatory Surgery Center Information 67
3.12.3 Revenue, Cost, Gross and Gross Margin 68
    3.13 Eifelhoehen-Klinik 69
      3.13.1 Company Profile 69
3.13.2 Ambulatory Surgery Center Information 70
3.13.3 Revenue, Cost, Gross and Gross Margin 71
4 Global Ambulatory Surgery Center Market Size by Type and Application (2012-2017) 73
    4.1 Global Ambulatory Surgery Center Market Size by Type (2012-2017) 73
4.2 Global Ambulatory Surgery Center Market Size by Application (2012-2017) 74
4.3 Potential Application of Ambulatory Surgery Center in Future 76 

Continued….

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1104328

Contact Us: sales@wiseguyreports.com

Ph: +1-646-845-9349 (US) ; Ph: +44 208 133 9349 (UK)

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

New York Corporate Whistleblower Center Now Urges a Nursing Home Employee in New York With Proof Their Employer Is Overbilling Medicare For Medical Treatments to Call About Rewards

We are convinced there probably a more than a few people in New York State who could be millionaires based on their inside information about Medicare fraud and healthcare companies”

— New York Corporate Whistleblower Center

WASHINGTON, DC, USA, October 24, 2017 /EINPresswire.com/ — The New York Corporate Whistleblower Center says, “We are urging a manager or an employee at a New York State nursing home, a skilled nursing facility, a dialysis center or a company providing hospice services to call us anytime at 866-714-6466 if they can prove their employer is involved in significant Medicare overbilling for needless medical treatments. Recently a small group of whistleblowers with this exact type of information received a $3.6-million-dollar reward.” http://NewYork.CorporateWhistleblower.Com

To illustrate what the New York Corporate Whistleblower Center is talking about in July 2017 the Department of Justice announced a Midwest based healthcare company has agreed to pay approximately $19.5 million to resolve allegations pertaining to the submission of false claims for medically unnecessary rehabilitation therapy and hospice services to Medicare.

The settlement resolves allegations that, from January 2008 through December 2012 the healthcare company submitted bills to Medicare for medically unnecessary rehabilitation therapy services at 18 skilled nursing facilities. The government contended that the therapy services were provided at excessive levels to increase Medicare reimbursement for those services.

According to the New York Corporate Whistleblower Center, “We are convinced there probably a more than a few people in New York State who could be millionaires based on their inside information about Medicare fraud and healthcare companies ripping off the federal government. If you possess this type of information please call us anytime at 866-714-6466. Why sit on a winning lotto ticket without ever knowing what it could be worth?” http://NewYork.CorporateWhistleblower.Com

Simple rules for a whistleblower from the New York Corporate Whistleblower Center: Do not go to the government first if you are a potential whistleblower with substantial proof of wrongdoing. The New York Corporate Whistleblower Center says, “Major whistleblowers frequently go to the government thinking they will help. It’s a huge mistake. Do not go to the news media with your whistleblower information. Public revelation of a whistleblower’s information could destroy any prospect for a reward. Do not try to force a company/employer or individual to come clean about significant Medicare fraud, overbilling the federal government for services never rendered, multi-million-dollar state or federal tax evasion, or a New York based company falsely claiming to be a minority owned business to get preferential treatment on federal or state projects. Come to us first, tell us what type of information you have, and if we think it’s sufficient, we will help you with a focus on you getting rewarded. We also want to emphasize our initiative is statewide throughout New York State including communities such as New York, Rochester, Albany, Yonkers, Syracuse, Schenectady, Utica, or Buffalo.

Unlike any group in the US the Corporate Whistleblower Center can assist a potential whistleblower with packaging or building out their information to potentially increase the reward potential. They will also provide the whistleblower with access to some of the most skilled whistleblower attorneys in the nation. For more information a possible whistleblower with substantial proof of wrongdoing in New York can contact the Whistleblower Center at 866-714-6466 or contact them via their website at http://NewYork.CorporateWhistleBlower.Com.

For attribution please refer to the July 2017 Department of Justice press release on this matter.https://www.justice.gov/opa/pr/three-companies-and-their-executives-pay-195-million-resolve-false-claims-act-allegations.

Thomas Martin
New York Corporate Whistleblower Center
866-714-6466
email us here


Source: EIN Presswire

Maine Mesothelioma Victims Center Now Urges a Navy Veteran with Mesothelioma in Maine to Call Them for Direct Access to The Nation’s Best Lawyers for Better Compensation Results

Call us a 800-714-0303 for the peace of mind in knowing you are talking directly with some of the nation’s premier mesothelioma compensation lawyers as opposed to a local car accident lawyer”

— Maine Mesothelioma Victims Center

NEW YORK, NEW YORK, USA, October 24, 2017 /EINPresswire.com/ — The Maine Mesothelioma Victims Center says, “We are urging a US Navy Veteran or shipyard worker in Maine who has just been diagnosed with mesothelioma or their loved ones to call us anytime at 800-714-0303 for almost instant access to some of the nation’s most skilled, experienced and capable mesothelioma attorneys. These extremely qualified fulltime mesothelioma attorneys consistently get the best possible financial compensation for their clients.

“If you are a Navy Veteran who now has mesothelioma because of exposure to asbestos on a navy ship or at a shipyard you will need the nation’s top lawyers working on your compensation claim as we would like to discuss anytime. Mesothelioma compensation claims for a US Navy Veteran can easily be in the hundreds of thousands of dollars or much more.” http://Maine.MesotheliomaVictimsCenter.Com

The Maine Mesothelioma Victims Center fears that many Navy Veterans with mesothelioma or their loved ones confuse VA disability payments with a lump sum settlement or settlements for mesothelioma. A VA monthly disability payment for mesothelioma may be around $1100 per month. A financial compensation settlement that is achieved by the Veteran’s mesothelioma attorneys could easily be in the hundreds of thousands of dollars or much more. The variable is how much exposure to asbestos did the Navy Veteran have during their time in the navy or after the navy. After the navy could include a job in a factory, a power plant, a public utility or as a skilled trades worker.

If the Maine Mesothelioma Victims Center had one vital piece of advice for a Navy Veteran, a shipyard worker or anyone in Maine with mesothelioma it would be, “Call us anytime at 800-714-0303 for the peace of mind in knowing you are talking directly with some of the nation’s premier mesothelioma compensation lawyers as opposed to a local car accident lawyer. When it comes to obtaining the best possible mesothelioma compensation the skill and the capabilities of the lawyer you hire matters.” http://Maine.MesotheliomaVictimsCenter.Com

The Maine Mesothelioma Victims Center would like to emphasize theirs is a statewide initiative available to a diagnosed victim anywhere in Maine including communities such as Bangor, Lewiston, Portland, Brunswick, Saco, Sullivan, Milltown, Bath, or Biddeford.

For the best possible treatment options in Maine the Maine Mesothelioma Victims Center strongly recommends the following heath care facility with the offer to help a diagnosed victim, or their family get to the right physicians at this hospital.

* The Maine Medical Cancer Institute: http://www.mmc.org/cancer-institute

High-risk work groups for exposure to asbestos in Maine include Veterans of the US Navy, power plant workers, shipyard workers, oil refinery workers, mill workers, factory workers, plumbers, electricians, auto mechanics, machinists, and construction workers. Typically, the exposure to asbestos occurred in the 1950’s, 1960’s, 1970’s, or 1980’s.

According to the CDC the average age for a diagnosed victim of mesothelioma is 72 years old. This year between 2500, and 3000 US citizens will be diagnosed with mesothelioma. Mesothelioma is a rare form of cancer that is attributable to exposure to asbestos.

According to the CDC the states indicated with the highest incidence of mesothelioma include Maine, Massachusetts, Connecticut, Maryland, New Jersey, Pennsylvania, Ohio, West Virginia, Virginia, Michigan, Illinois, Minnesota, Louisiana, Washington, and Oregon. http://Maine.MesotheliomaVictimsCenter.Com

For more information about mesothelioma please refer to the National Institutes of Health’s web site related to this rare form of cancer: https://www.cancer.gov/types/mesothelioma.

Michael Thomas
Maine Mesothelioma Victims Center
800-714-0303
email us here


Source: EIN Presswire

Spinal Cord Injury – Pipeline Review, H2 2017- Understanding the Focus Areas of Leading Companies

Spinal Cord Injury

PUNE, MAHARASHTRA, INDIA, October 24, 2017 /EINPresswire.com/ —

SUMMARY

WiseGuyReports published new report, titled “Spinal Cord Injury – Pipeline Review, H2”

Pharmaceutical and Healthcare disease pipeline guide Spinal Cord Injury – Pipeline Review, H2 2017, provides an overview of the Spinal Cord Injury (Central Nervous System) pipeline landscape.
Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida or Friedreich's ataxia. Signs and symptoms of spinal cord injury include extreme back pain or pressure in the neck, head or back, paralysis in any part of the body, numbness, tingling or loss of sensation in the hands, fingers, feet or toes, loss of bladder or bowel control, difficulty in walking and impaired breathing after injury.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2400886-spinal-cord-injury-pipeline-review-h2-2017

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Spinal Cord Injury – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Spinal Cord Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Spinal Cord Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 9, 8, 1, 29 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 15 and 2 molecules, respectively.
Spinal Cord Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Spinal Cord Injury (Central Nervous System).
– The pipeline guide reviews pipeline therapeutics for Spinal Cord Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Spinal Cord Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Spinal Cord Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Spinal Cord Injury (Central Nervous System)

Key points to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Spinal Cord Injury (Central Nervous System).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Spinal Cord Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Spinal Cord Injury – Overview
Spinal Cord Injury – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes

..CONTINUED

About Us

Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Ulcerative Colitis Pipeline Review, H2 2017- Identify Key Business Opportunities

Ulcerative Colitis

PUNE, MAHARASHTRA, INDIA, October 24, 2017 /EINPresswire.com/ —

SUMMARY

WiseGuyReports published new report, titled “Ulcerative Colitis – Pipeline Review, H2”

Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis – Pipeline Review, H2 2017, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape.
Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2400881-ulcerative-colitis-pipeline-review-h2-2017

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ulcerative Colitis – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ulcerative Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 10, 37, 26, 1, 50, 13 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 1 molecules, respectively.
Ulcerative Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Ulcerative Colitis (Gastrointestinal).
– The pipeline guide reviews pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Ulcerative Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Ulcerative Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Ulcerative Colitis (Gastrointestinal)

Key points to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Ulcerative Colitis (Gastrointestinal).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Ulcerative Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents
Introduction
Ulcerative Colitis – Overview
Ulcerative Colitis – Therapeutics Development
Ulcerative Colitis – Therapeutics Assessment
Ulcerative Colitis – Companies Involved in Therapeutics Development
Ulcerative Colitis – Drug Profiles
Ulcerative Colitis – Dormant Projects

..CONTINUED

About Us

Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire